Remus Pharmaceuticals Limited (NSE:REMUS)
India · Delayed Price · Currency is INR 820.55
-20.95 (-2.49%)
At close: Sep 12, 2025
Remus Pharmaceuticals Revenue
In the fiscal year ending March 31, 2025, Remus Pharmaceuticals had annual revenue of 6.20B INR with 191.44% growth. Remus Pharmaceuticals had revenue of 3.48B in the half year ending March 31, 2025.
Revenue
6.20B
Revenue Growth
+191.44%
P/S Ratio
1.56
Revenue / Employee
n/a
Employees
48
Market Cap
9.67B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 6.20B | 4.08B | 191.44% |
| Mar 31, 2024 | 2.13B | 1.68B | 371.63% |
| Mar 31, 2023 | 451.32M | 204.15M | 82.59% |
| Mar 31, 2022 | 247.17M | 59.09M | 31.42% |
| Mar 31, 2021 | 188.08M | 63.89M | 51.44% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Reliance Industries | 9,765.41B |
| HDFC Bank | 2,736.06B |
| Bharti Airtel | 1,839.41B |
| Tata Consultancy Services | 2,561.48B |
| ICICI Bank | 2,054.85B |
| State Bank of India | 3,503.84B |
| Infosys | 1,672.76B |
| Bajaj Finance | 387.76B |